CHINA HEALTHCARE PULSE

2Q/1H Wrap up: Re-entry thesis playing out; CDMOs lead while assessing next leg of healthcare re-rating

We highlighted the window for derisked re-entry in early July post mid-year corporate day. The thesis is playing out, with **CRO/CDMOs as clear winners,** significantly outperforming broader healthcare, driven by earnings beats, guidance upgrades and exceptionally strong order momentum. More importantly, the **recovery is no longer confined to commercial manufacturing, particularly GLP-1, with increasingly tangible signs of improving demand in the earlier stages of the R&D cycle, particularly emerging modalities and CMO business beyond GLP-1.** Stabilizing biotech funding, active global licensing-out/BD/M&A activity, rising capex commitment and accelerating AIDD adoption further reinforce confidence that the current recovery is evolving into a more durable growth cycle while increasing commercial manufacturing visibility provides stronger support beyond 2026. Investor positioning remains supportive with more incoming generalist interest, despite periodic profit taking amid shareholder-disposal concerns and recurring geopolitical headlines. ***Buy: WuXi AppTec, WuXi XDC, Pharmaron (H), Asymchem (H), Tigermed and GenScript.*** We will host our 2nd Asia Healthcare CDMO Day in **Singapore (Sep 22-25)**.

Beyond CDMOs, investor attention is increasingly **shifting toward China's next innovation cycle**. Easing anti-corruption concerns post 2Q prints vs. May/June, improving profitability, accelerating go-global execution are supporting sentiment, with growing focus on the ability to translate innovation into sustainable value creation. **WCLC (Sep) and ESMO (Oct) provide an important catalyst window, particularly for ADCs (TROP2, DLL3, B7H3), PD-1/VEGF and RAS-targeted therapies.** A positive readout could strengthen confidence in China's innovation ecosystem and support further re-rating opportunities for globally competitive innovators. ***Buy: BeOne, Innovent, Kelun Biotech, Keymed, GenFleet and Hansoh.***

In MedTech and Services, domestic recovery remains gradual, although with more visible signs of an inflection. Improving procurement activity, channel normalization and equipment replacement demand are supporting sentiment toward capital equipment and IVD names; **Buy: *Mindray and United Imaging*. Globalization** remains the clearest source of differentiation, ***Angelalign and Edge Medical*** continue to deliver superior growth and earnings visibility.

Ziyi Chen
+852-2978-0526 ziyi.chen@gs.com
Goldman Sachs (Asia) L.L.C.

Chris Pan, CFA
+852-2978-7993 chris.pan@gs.com
Goldman Sachs (Asia) L.L.C.

Tianyi Yan
+86(21)2401-8609
tianyi.yan@goldmansachs.cn
Goldman Sachs (China) Securities Company Limited

Linhai Zhao, Ph.D.
+852-3966-4059 linhai.zhao@gs.com
Goldman Sachs (Asia) L.L.C.

Honglin Yan
+852-2978-6666 honglin.yan@gs.com
Goldman Sachs (Asia) L.L.C.

Michael Zheng
+86(21)2401-8928
michael.zheng@goldmansachs.cn
Goldman Sachs (China) Securities Company Limited

Eddie Song
+852-2978-6426 eddie.song@gs.com
Goldman Sachs (Asia) L.L.C.

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to www.gs.com/research/hedge.html. Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.

Key takeaways by sub-sector

China Healthcare

Next wave of transformation: clinical demand focused R&D, collaborations & going global

Explore >



CDMOs - strong earnings delivery, guidance upgrades and improving growth visibility

- **Broad-based earnings beats, guidance upgrades and strong order momentum reinforce sector fundamentals.** Most CDMOs delivered solid 2Q/1H26 results despite greater-than-expected FX headwinds, with WuXi AppTec, WuXi Biologics and WuXi XDC reporting meaningful earnings outperformance driven by improving utilization, operating leverage and increasing contribution from higher-value modalities. Guidance upgrades was another key highlight, with WuXi AppTec, WuXi Biologics, Pharmaron and GenScript all raising FY26 outlooks, reinforcing improving earnings visibility and supporting further consensus upgrades into 2027. Robust backlog and order growth across the sector, including WuXi AppTec (+25%), WuXi Biologics (+24%), WuXi XDC (+50%), Asymchem (+54%) and Pharmaron (+30%), further strengthen confidence in medium-term growth visibility.
- **Recovery is broadening beyond commercial-stage execution into early-stage innovation.** While GLP-1, ADC and commercial manufacturing remain key growth drivers, earnings results also highlighted improving activity across discovery, preclinical and early clinical development. WuXi AppTec reported a sharp rebound in preclinical and Phase I molecule additions, WuXi Biologics added a record 169 integrated projects, WuXi XDC signed a record 51 integrated projects, and Pharmaron delivered 30% growth in Clinical Development order intake. In our view, these trends suggest the sector recovery is becoming increasingly broad-based, supported by improving biotech funding conditions, active BD/licensing activity and continued innovation demand globally.
- **Capex expansion and AIDD adoption underscore confidence in long-term demand.** Several companies raised or accelerated investment plans during the quarter, particularly in peptides, ADCs, oligonucleotides, biologics manufacturing and global capacity expansion, reflecting confidence in backlog conversion and future demand. At the same time, AIDD is increasingly becoming a tangible growth contributor rather than a long-term concept. GenScript significantly upgraded guidance on accelerating AIDD demand, while Pharmaron, WuXi Biologics and others highlighted increasing AI-related customer activity and project opportunities. Together, rising capex commitments and growing AIDD demand reinforce our view that industry growth is being supported by both near-term execution and long-term innovation trends.

Biotech: profitability inflects while go-global execution moves from planning to delivery

- **Strengthening financials supported by BD income and operating leverage:** The 1H26 earnings generally reflected a combination of steady commercial performance, increasing BD contributions and continued cost discipline: **1) innovative drugs ramp-up remained resilient** amid anti-corruption campaign, which was consistent with the Corp Day takeaway; we saw companies like Innovent / Kelun Biotech / InnoCare / KeyMed showing strong 1H26 product sales with clear clinical benefits and expanded coverage; **2) broader BD income**, as more biotech companies received near-term BD income (e.g. upfront payments, near-term milestones), strengthening the cash position (e.g. Antengene, Jacobio, Abbisko); and **3) strengthening bottom-line**, with continued operating leverage for established biotech names (Innovent, BeOne) and extended cash runway for small biotech with continued cost discipline and strengthened cash through BD income and funding. Importantly, investor discussions have increasingly shifted from whether companies can achieve break-even to the durability / quality of earnings, with greater scrutiny on sustainable operating leverage, commercialization execution and capital allocation discipline. We believe the improving cash position (e.g. US$4.5bn of cash and equivalents for Innovent by end of July) provides greater flexibility to support both internal pipeline investment and global expansion initiatives.
- **Global pathway discussion coming into focus:** With continued pipeline progress across the sector, we saw increasing investor discussion on global registrational pathway for key pipeline assets, with focus on tangible regulatory and commercial milestones that can show a credible, funded path to global registration: for example, **Innovent** reiterated confidence to deliver 5+ programs reaching ph3 MRCT by 2030, with IBI363 (PD-1/IL-2α) continuing to broaden beyond its lead IO-resistant NSCLC indication into further global registrational planning (1L NSCLC/CRC planned in 2027); **Kelun Biotech** is expecting the first wave of global ph3 readouts for sac-TMT in the next 12 months, which we expect to strengthen the conviction for "China-to-Global" clinical data translation; **Ascletis** has initiated two global Ph3 trials (AURORA-1/2, c.4,600 patients) for oral GLP-1 ASC30 in obesity, with topline data expected 3Q28; **CStone's** CS2009 is at a similar planning-to-initiation inflection, with FDA consultation on global ph3 MRCT design (1L NSCLC/CRC) targeted in 4Q26 and the first registrational trials to start by YE26. Taken together, these examples suggest the market's go-global lens is maturing — from potential BD news headline to more concrete value-creation pathway as China biotech companies are building resources / willingness to participate more in the global drug development.
- **WCLC / ESMO as near-term catalysts, shifting focus in top therapeutic fields:** As the 1H26 earnings wrapping up, we highlight WCLC (Sep) / ESMO (Oct) as two approaching medical conferences, with eyes on: 1) Lung06 data for sac-TMT (TROP2 ADC, Kelun Biotech) at ESMO, which we reiterate the expectation of 9-12m PFS for 1L nsqNSCLC with PD-L1 TPS<1%; 2) zoci (DLL3 ADC, Zai Lab) data debut in 1L SCLC at ESMO, expected to detail ORR, 6m-PFS (8-9 months of follow-up, vs. mPFS of 5m for SOC), and safety profiles across c.60 patients (recall Amgen's DeLLphi-305 1L Tarlatamab/PD-L1 combo delivered OS win recently) ; 3) GFH276 (pan-RAS inhibitor, GenFleet) clinical debut at ESMO, with eyes on the clinical validation on its potentially wider therapeutic window compared to daraxonrasib; and 4)

PD-1/VEGF updates, with HARMONi-2 OS update (ivonescimab, Akeso) at WCLC, and CS2009 (PD-1/VEGF/CTLA-4, CStone) updates (mono and combo) at ESMO. More broadly, we note the incremental shift of investor sentiment in top therapeutic fields, with 1) increasing interest on mRNA cancer vaccine and RAS-target therapies, given the recent positive industry updates; while 2) cautious towards PD-1/VEGF – the updated PFS HR for China ph3 HARMONi-6 (from 0.6 to 0.72) has raised investor debates on whether the upcoming global ph3 HARMONi-3 readout (final PFS / interim OS, by SMMT) can clear the <0.75 PFS HR threshold that our US analysts view as necessary to support a statistically significant OS benefit.

Pharma: Incremental positive for commercial execution; Go-global execution visibility improving

- **Innovative drug sales growth remains resilient despite industry headwinds:** Across the sector, 2Q/1H26 results suggest that recent anti-corruption tightening has created near-term commercial disruption rather than structural demand destruction. Most companies suggested reduced hospital academic activities during 2Q, but management teams generally indicated sequential improvement through July-August, with activity levels largely normalizing by late August. In addition, the impact has been highly product-specific rather than therapy-specific. Differentiated innovative products continued to deliver strong growth, including Hansoh's Ameile (EGFR TKI), Keymed's Stapokibart (IL-4Rα mAb), InnoCare's Orelabrutinib (BTK inhibitor), Innovent's Mazdutide (GLP-1/GCGR) and Luye's Ruoxinlin (ansofaxine). By contrast, products facing pricing pressure, lifecycle maturity or increasing competition, such as Hengrui's older oncology portfolio (e.g. apatinib/pyrotinib), generic drugs and selected biosimilars, were under pressure. We believe the key message from this earnings season is that Chinese pharma is increasingly transitioning from a promotion-driven model toward a product-driven model, where commercial performance is increasingly determined by clinical differentiation rather than salesforce intensity. Beyond divergent sales performance, improving operating leverage also emerged as a common theme, with reduced academic promotion activities and efficiency gains driving lower SG&A expenses. As a result, several companies delivered earnings growth ahead of revenue growth, including Sino Biopharm (+63% YoY core profit growth) and Hansoh (+19% YoY profit growth excl. Investment gains).

- **Global innovation broadens beyond oncology:** Pipeline R&D updates continued to reinforce the diversification of China's innovation landscape. In autoimmunity, Hengrui's SHR-1139 (IL-23/IL-36 bispecific) emerged as one of the most differentiated assets, with management expecting to initiate global Phase III studies in 2H26 following FDA interactions. The asset achieved 100% PASI90 in a small Phase I cohort. Meanwhile, SHR-2173 (IFNAR1/TACI fusion protein) demonstrated 69% SRI-4 responses in early SLE studies, comparing favorably with existing biologics. In cardiometabolic diseases, investor focus remains on UBT251 (GLP-1/GIP/GCGR) under Novo Nordisk's global development, alongside Hengrui's oral Lp(a) inhibitor HRS-5346, which entered Merck-led Phase II development and achieved 86.3% Lp(a) reduction, as well as HRS-1893 (myosin inhibitor), which continues to show potential BIC characteristics in HCM. ADC and bispecific globalization remains another key theme, led by Hansoh's B7-H3 ADC (HS-20093) and B7-H4 ADC (HS-20089)

under GSK, while CSPC's EGFR ADC and PD-1/IL-15 bispecific continue to attract partner interests. Following MRNA/MRK's first mRNA cancer vaccine's Phase III success, CSPC's mRNA platform has also gained attention, with its therapeutic HPV mRNA vaccine advancing into Phase II and a colorectal cancer neoantigen vaccine recently filing IND. Overall, we believe investor focus is increasingly shifting away from near-term commercialization disruptions toward a new cycle of value inflection driven by global R&D execution spanning autoimmune, cardiometabolic, neurology diseases and globally competitive ADC/bispecific platforms.

Medtech & Service - Gradual Recovery Underway; Globalization and Shareholder Returns Remain Key Differentiators

- **A key common theme from this earnings season is gradual operational recovery,** but without a broad-based domestic demand rebound. In healthcare services, companies such as **Hygeia and Gushengtang** reported resilient patient traffic, improving surgical volumes and stable underlying demand, while management teams highlighted better operating discipline and more selective expansion strategies. In medtech, earnings pressure from prior VBP implementation appears to be easing, with profitability improving sequentially at names such as **Weigao**, supported by product mix optimization, cost controls and improving operating leverage. Nevertheless, management commentary across the sector remains cautious, as pricing pressure, hospital budget constraints and procurement disruptions continue to cloud visibility on the timing and magnitude of a full recovery.
- **Globalization continues to emerge as the clearest differentiator and one of the most important drivers of investor interest.** Companies with visible overseas execution generally delivered stronger growth, better margins and more positive earnings revisions. **Angelalign** raised FY26 total case-volume guidance to 700k (+32% y/y), including 350k overseas cases (+37% y/y), while achieving overseas profitability ahead of schedule with overseas revenue growing 65% y/y in 1H26; **AK Medical** reported 42% y/y overseas revenue growth, significantly ahead of domestic growth (+3% y/y), helping lift gross margin by 4.6ppt and reinforcing management's view that globalization remains its top strategic priority; **Edge Medical** continued to demonstrate strong overseas commercialization, with 49 of 58 systems installed or delivered in 1H26 overseas, bringing cumulative overseas installations to 103 systems, while overseas revenue contribution reached nearly 70% of total sales. Even for larger and more mature platforms such as **Weigao**, overseas revenue still grew 6.2% y/y and now accounts for 25.2% of group sales, highlighting international markets as a key structural growth driver. Across the sector, the earnings season reinforced the view that companies with scalable global franchises are increasingly able to offset domestic policy uncertainty and differentiate themselves from peers more reliant on China demand alone.
- **Shareholder returns remain a key focus across the sector, although investor attention continues to be primarily driven by recovery and globalization.** Several companies reiterated previously announced capital-allocation frameworks, reflecting growing confidence in free cash flow generation and a more disciplined approach to expansion. **Angelalign** announced a total dividend of HK$4.57/share, comprising a HK$4.10/share special dividend and

HK$0.47/share interim dividend, following the earlier-than-expected overseas profitability inflection. **Gushengtang** reaffirmed its commitment to distribute at least HK$450mn annually, maintain a dividend payout ratio of no less than 60%, and announced an additional HK$300mn buyback program, implying a dividend yield of roughly 7% based on trailing distributions. **Hygeia** similarly emphasized shareholder returns, earmarking approximately Rmb500mn per year during 2026-28 for buybacks and dividends, supported by improving free cash flow generation (+38.5% y/y in 1H26) and a more disciplined capex strategy. While shareholder returns have been a recurring theme over recent quarters, management teams appear increasingly comfortable balancing growth investments with cash distribution as domestic expansion opportunities become more selective. We believe investors remain more focused on recovery trends and overseas execution, although sustained capital returns could provide incremental valuation support over time.

Capital equipment: The domestic market has reached an inflection point while international momentum remains robust

- According to our tracker, domestic winning bids turned positive year-on-year in June and July, a recovery corroborated by United Imaging's interim report showing YoY revenue growth in large medical imaging equipment; although Mindray's medical device segment has not yet returned to positive growth, its channel inventory has fallen to low levels and is expected to decline further within the year per the company. This domestic rebound is primarily driven by trade-in funding that United Imaging expects to fully utilize within the year and at a faster pace than in the previous two years, as operational processes have become significantly smoother after two years of implementation. Additionally, equipment procured during the Covid period, such as patient monitors and ventilators, is now entering its replacement cycle, providing further impetus to the industry's recovery. Overseas business continues to expand rapidly, with United Imaging posting over 50% YoY growth and Mindray sustaining around 10%, though the latter's reported growth understates actual performance due to adverse currency translation effects.

Diagnostics: China market saw inflection point while going global remains attractive

- The domestic IVD market showed initial signs of recovery in 2Q26, driven by a combination of accelerating share gains among leading domestic players, normalization of distributor inventories and testing demand, and a diminishing incremental impact from previous price cuts. In particular, the staggered rollout of the 28-province tumor marker and thyroid-function reagent VBP across provinces from this March onward began to translate previously secured procurement shares into actual reagent volumes, while reagent pull-through from high-end analyzer and TLA placements over the past 1-2 years also became more visible. Meanwhile, industry consolidation has been ongoing for several quarters. What changed in 2Q was that the resulting share gains began to outweigh residual pricing and demand headwinds in the reported results of several leading IVD companies, and we saw companies like Mindray and SNIBE report significant gains in market share, underscoring the ongoing shift toward local alternatives. Overseas expansion

remains robust, with top Chinese IVD players still holding less than 5% of international markets, indicating substantial room for further growth.

- Meanwhile, independent clinical laboratory (ICL) providers have clearly reached an inflection point, with Kingmed and Dian Diagnostics showing notable improvements in gross margins and pointing to rising industry consolidation. Regarding the policy on standardized pricing for testing services, both ICL and IVD companies expect a phased rollout beginning with pilot programs in six provincial-level administrative regions before nationwide implementation, with anticipated price reductions being relatively moderate—a prospect that exceeds prior market expectations. ICL firms believe further price cuts could drive higher outsourcing rates for diagnostic testing, while IVD manufacturers see the policy as another catalyst for accelerating domestic substitution.

Retail Pharmacy: Sector rebounds with rising concentration

- Based on data from three leading pharmacy chains we cover (see their 1H26 earnings review: Yifeng, Dashenlin, and LBX) and sample pharmacies tracked by Pharmcube (see link), China's retail pharmacy sector reached a clear inflection point in the first half of 2026. The total number of operating stores has turned positive year-on-year, with month-on-month growth recorded for five consecutive months through July, while average revenue per store has sustained year-on-year increases since May 2025.
- However, the overall industry recovery does not signal a synchronized expansion cycle across all players; instead, the market remains in a phase of consolidation and rising concentration. The current policy environment favors industry leaders in integrating smaller chains and independent pharmacies (see our analysis of the policy), as evidenced by Yifeng and Dashenlin completing acquisitions in 1H26, while LBX has maintained its full-year target of acquiring 300 stores despite no deals being finalized yet.
- Looking ahead to the second half of 2026 and 2027, we expect leading pharmacy chains to continue outperforming the broader industry. Their primary drivers of same-store sales growth include innovative drugs such as GLP-1 agonists, oncology medications, and dermatological treatments, as well as non-pharmaceutical categories like health supplements and functional foods, complemented by external expansion through new self-operated stores, franchising, and mergers and acquisitions.

Plasma: Continued over-supply concern

- The sector saw decline in both revenue and gross margin, which validates our earlier concerns that the plasma product market has entered a phase of oversupply (see China Healthcare: Plasma FY25 & 1Q26 wrap-up: Rising over-supply concern; Downgrade Hualan to Neutral). On the demand side, prices for certain products have fallen following the implementation of volume-based procurement (VBP), while the rollout of DRG/DIP payment reforms has further

curtailed product utilization; meanwhile, on the supply side, major plasma product manufacturers continue to expand their plasma collection volumes. Given these dynamics, we anticipate further consolidation within the blood products industry, leading to increased market concentration.

Vaccine: Continue in trough

- Although the vaccine industry has passed through the trough of destocking caused by anti-corruption measures in the CDC system, it still faces: 1) A decrease in ASP due to VAT adjustments; 2) Insufficient demand caused by a low birth rate; 3) Vaccine hesitancy issues; 4) Intensified competition. We believe the future development trends of the industry include: 1) Sales growth of elderly-related vaccines will be faster than that of vaccines targeting infants and young children; 2) The development of multivalent vaccines and tumor-related vaccines will become new hot spots in the future.

Insulin: Domestic substitution & going global

- Affected by VAT adjustments, the ASPs of the insulin companies we cover (Gan & Lee and Tonghua Dongbao) have all been impacted. However, both companies stated that the current room for domestic substitution is still very large, and therefore the prospects for the Chinese market remain favorable. In addition, both companies are actively expanding overseas: Gan & Lee got approvals for all three 3rd gen insulin from EU, while THDB received US FDA approval for its insulin aspart.

Our key investment thesis and preferred stocks by sector

Exhibit 1: We Prefer CDMO, Selective Pharma/Biotech; More Cautious on Medical Consumables & Services

Summary of 2026 by-segment view and thesis

Segment	Segment View	Preferred Stocks
CRO/CDMO	**Structurally Positive** Broader recovery signals are emerging across CRO/CDMOs, supported by improving order momentum, book-to-bill trends and biotech funding. While GLP-1 and bioconjugates remain key growth drivers for sector leaders, recovering early-stage R&D activity and incremental demand from AIDD could support a more broad-based earnings recovery across the sector.	Continue to favor leading CRO/CDMO franchises best positioned to capture global product-cycle tailwinds, including **WuXi AppTec** and **Asymchem**, while we see increasing opportunities in **WuXi XDC** and **Pharmaron** as improving biotech funding and early-stage demand recovery could drive higher operating leverage, given their greater exposure to early-development activities; and **Tigermed** for acclerating order momentum in 1H26
Biotech	**Selective** Go-global trend is muti-year structural, whilst multiple transitions are ongoing in 2026: beta to alpha, single asset to platform, deal making to global development execution. Rich catalysts remain the key to stay on investor radar and generate returns	We see holding onto leading, event-rich larger-cap ($10bn+) platform names as more balanced strategy, prefer **BeOne** (potential upside from solid tumor data, with five cornerstone programs entering global ph3 trials); **Kelun Biotech** (Strong data visibility for sac-TMT in China / global ph3 trials: 1st global approval in early-27); **Innovent** (reinforced China visibility in 2030, potential upside from growing global pipeline); More selective on smaller biotech names that hinge on key data readouts. e.g. **Henlius** (sales expansion from overseas biosimilar, license-out potential for HLX43/HLX22); **CStone** (ph2 data of TsAb CS2009), **Abbisko** (FDA approval of pimicotinib, ph2 data of FGFR2/3); **GenFleet** (clinical debut of GFH276) and **Keymed** (global phase 3 data for CLDN18.2 ADC at ESMO; global phase 3 trials initiation by Gilead in 2027).
Pharma	**Increasingly Positive** China commercialization saw sequential improvements in 3Q, and innovative drug sales stayed resilient. Pipeline development further expanded with emerging non-oncology assets showing better-in-class potential, and overseas visibility continued to improve.	We prefer **Hansoh** (Solid earnings growth for China commercialization and growing visibility from overseas pipeline delivery); **SBP Group** (Earnings continue to benefit from expense saving; more BD deals to come); **CSPC** (Recovery of finished drug sales from low base; leading position in mRNA vaccine)
Retail Pharmacy	**Increasingly Positive** Earnings inflection for leaders - both store count and single-store sales growth are improving	More optimistic about **Yifeng (Buy)** and **Dashenlin (Buy)** - strong balance sheet with more cash on hand for strategic flexiblity (e.g. M&As) and higher operational efficiency.
MedTech	**Stay Neutral** Medtech fundamentals are gradually stabilizing, with overseas expansion and commercialization execution remaining the key drivers of outperformance. Continue to monitor the policy impact on surgical volumes and upcoming VBP on equipment	Prefer companies with strong globalization execution, including **Angelalign, United Imaging and Edge Medical**, while seeing improving sentiment toward **Mindray** as domestic growth stabilizes and overseas expansion remains solid
Healthcare Services	**Relatively Cautious** Lingering DRG/DIP pressure and diverging discretionary consumption; Recovery uneven by region and service mix	Prefer platforms with more resilient, non-discretionary demand profiles (**Buy Gushengtang**); Also more constructive on **Aier (Buy)** as it is upgrading its refractive surgical service with new technology and higher value consumables; Conversely, we remain more guarded on names exposed to structural demographic pressures, where recovery signals remain uneven (Sell Topchoice)
Plasma	**Relatively Cautious** The sector is under a over-supply situation, amid ASP decreasing due to VAT adjustment	We are more cautious within this sector, and we are Neutral on Hualan

公众号：弘研先知 微信：DYXZ0524
独家的一手信息，独立的行业思考

Source: Company data, Goldman Sachs Global Investment Research

Guidance summary

Exhibit 2: Guidance summary

		2Q26/1H26 earnings			
	Guidance for FY26 and beyond	**Guidance change**	**Key highlights from earnings call**	**2Q26/ 1H26**	**Miss / Beat / Inline**
CRO/ CDMO					
WuXi Apptec	FY26 revenue growth of 35-39% for continuing operations; TIDES 45% y/y; Capex at Rmb7 5-8 5bn, adj FCF at Rmb13 5-14 5bn	Up	Strong growth underpinned by backlog expansion, robust order momentum, and continued strength across small molecule D&M, TIDES, and Testing; visibility continues to improve	2Q26	Beat
WuXi XDC	35%+ for standalone and 40%+ as on consolidated on a constant-currency basis at the group level, and expects FY26 gross margin to remain broadly stable versus FY25	-	1H26 earnings beat on stronger-than-expected order momentum; commercial visibility continue to improve	1H26	Beat
WuXi Bio	FY26 revenue growth guidance of 15-18% y/y (20-23% at constant currency); FY26/27 capex plan of c Rmb7. 1bn/8bn	Up	Margin expansion drove strong earnings beat; FY26 topline guidance raise to 15-18%	1H26	Beat
Pharmaron	FY26 revenue growth at 15-20% y/y, incorporating a c.3% FX headwind; margins continue to improve sequentially. FY26 Capex at c Rmb3 6bn (+1bn from FY25 level)	Up	Strong CDMO order momentum supports FY26 guidance raise to 15-20%	2Q26	Beat
Asymchem	19-22% y/y revenue growth in FY26, incorporating a 2-3% FX headwind; FY26 capex guidance at Rmb2.6-2 8bn, and FY27 capex exceed Rmb3bn	-	Slower 2Q26 earnings on project timing with 2H26 acceleration expected; strong order and accelerating capex supports LT outlook	2Q26	Miss
Genscript	By segment revenue growth: LSG 25-30% (with adjusted GPM/OPM at 55%/25%). ProBio. 25-30% for fee-for-service. Bestzyme: 8-10%	Up	AIDD as a key driver for LSG beat, fuels sharp guidance raise in FY26	1H26	Beat
Tigermed	Double-digit revenue growth in FY26, and full-year order growth to come in higher than prior guidance (previously: new order growth not lower than FY25)	Up	Order growth accelerated and pricing improved; recovery outlook gaining traction	2Q26	Inline
MedDevice					
AngelAlign	Raised FY26 total case-volume guidance to 700k (+32% y/y, from +25% previously), with overseas at c.350k (+37% y/y, from c.340k/+33%) and China at c.350k (+27% y/y, from c.325k/+18%, not factoring in the upcoming VBP)	Up	Raised FY26 case guidance on strong volume momentum; overseas break-even achieved ahead of plan	1H26	Beat
Edge Medical	The FY26 installation/delivery target was raised to 130+ units (from c.120 previously), including c.25 domestic and c.110 overseas. Reiterated full-year guidance of c.Rmb850mn revenue, gross margin sustained at the 1H26 level of c 64%, and a full-year breakeven	-	Higher installation target reinforces overseas commercialization momentum	1H26	Beat
AK Medical	Maintained full-year guidance: revenue and earnings to grow at a similar momentum to FY25	-	Resilient earnings growth; strong overseas momentum supporting full-year guidance delivery	1H26	Beat
MicroTech	≥40% revenue growth, with CGM expected to outgrow the group. Gross margin continue to improve, and net profit growth to outpace revenue growth in FY26	Up	Robust growth driven by domestic CGMS scale-up; raised FY26 guidance	1H26	Beat
Weigao	FY26 revenue growth 3-5% (excluding consolidation), net profit to improve in 2H; capex guidance remains at Rmb600-800mn; and maintained 50% dividend payout ratio	-	1H26 earnings softened on a high base; full year revenue guidance of 3-5% unchanged	1H26	Inline
Tinavi Medical	EBITDA and NP breakeven in 2026E/27E; maintained its FY26 target of 60+ installations	-	2Q earnings miss on slower hospital capex; eyes on 2H tender recovery and policy impact	2Q26	Miss
Lepu	No more aesthetics revenue guidance	Down	Aesthetics/obesity/BCI pipeline	1H26	Miss
United Imaging	Revenue growth of 20% in 2026	-	Overseas revenue grew 54% in 1H26, while domestic market share gained 1.7 ppt	1H26	Beat
SNIBE	Expect China revenue growth to recover to positive within FY26, while guiding 15%-20% yoy growth overseas in 2026	Down	Going global; Fx loss: Milder than expected ASP cut from diagnostic service price unification	1H26	Beat
Mindray	Expect China revenue growth to recover to positive within FY26	-	1) Channel de-stocking will continue in 2H26, 2) Domestic IVD market share increasing, 3) Fx loss put pressure on NPM, 4) Emerging business, incl. APT Medical, pet care, etc., continuously grew over 20% yoy	1H26	Beat
Pharma					
Hengrui	Rmb19.2bn for innovative drug sales in 2026 and 25% growth for 2027/28	-	30% growth for innovative drug sales in 2026 is challenging; Sequential improvement in 3Q	2Q26	Miss
Hansoh	Double-digit sales growth guidance maintained	-	Guides double digit growth in 2026 for both product sales and collaboration income	1H26	Beat
Fosun Pharma	maintained guidance of 20% CAGR over 2025-2027 for both innovative product sales and earnings	-	Rmb25bn innovative drug revenue ambition by 2029	2Q26	Inline
SBP Group	Double-digit growth in both total sales and core earnings for 2026	-	SG&A ratio to maintain at ~35% of total sales	1H26	Beat
CSPC	Positive growth guidance maintained for 2026	-	mRNA platform highlighted	2Q26	Beat
Livzon	A narrower magnitude of sales decline in 2H26 and earnings growth to outperform revenue	Down	A new product cycle is emerging, including IL-17A/F, P-CAB and aripiprazole microspheres	2Q26	Miss
CMS	modestly revised its FY26 revenue growth guidance to 15-20% from 20%+; potential earnings upside from investment gains in 2H	Down	Ruxolitinib cream guidance unchanged while growth in 2027 hinges on NRDL	1H26	Inline
Luye	20%+ earnings growth in 2026	Down	Target Rmb12bn revenue by 2030	1H26	Mixed
Gan & Lee	NP to reach Rmb1.100mn in FY26	-	Pipeline progress, (including GLP-1, QW insulin, etc.	1H26	Miss
3S Bio	No guidance	n.a	707 global execution as the key value driver with encouraging clinical progress	1H26	Mixed
United Lab	A slight decline of total revenue	-	API fundamentals continue to improve as pricing recovers and growth shifts downstream	1H26	Inline
TonghuaDongbao	No guidance		Domestic substitution trend & going global	1H26	Beat
Pien Tze Huang	No earnings call		No earnings call	1H26	Miss
Sichuan Kelun	No guidance		Infusion business saw the inflection point	1H26	Beat
Huadong	No guidance		Aethetic business may see some improvement in 2H; Innovative pipeline	1H26	Miss

Source: Company data, Data compiled by Goldman Sachs Global Investment Research

Exhibit 3: Guidance summary (cont'd)

		2Q26/1H26 earnings			
	Guidance for FY26 and beyond	Guidance change	Key highlights from earnings call	2Q26/ 1H26	Miss / Beat / Inline
Biotech					
BeOne	$6.6bn-$6.8bn for FY26 sales; $4.8bn-$5.0bn GAAP operating expenses; US$1.0-1.1bn GAAP EBIT	Up	2Q beat & raise with major step-up in FY26 EBIT; Rapid progress in solid tumor pipeline	2Q26	Beat
Everest Medicines	Rmb10bn/15bn for FY28/FY30	n.a.	1H sales miss in Nefecon/Xerava: Eyes on integration/execution as BD remains the growth driver	1H26	Miss
ZLAB	Pressure on FY26 sales, meaningful growth in FY27	-	2Q sales inline with sequential recovery; On-track development for zoci/ZL-1503	2Q26	Inline
Innovent	Rmb20bn in 2027, Rmb35-40bn, 5+ ph3 MRCT in 2030	New	1H profit beat with operating leverage; Target Rmb35-40bn by 2030	2Q26	Beat
Kelun Biotech	-	n.a.	1H sac-TMT sales beat; Lung06 data as major focus with novel ADCs entering clinical stage	1H26	Beat
Legend	EBIT (ex. FX) break-even in FY26	-	2Q marks first quarter of profitability, eyes on in-vivo CAR-T data updates	2Q26	Inline
Innocare	Management maintained guidance of >35% product sales growth in FY26, while indicating potential upside and possible guidance revision following 3Q results.	-	Autoimmune franchise approaching a major inflection point	2Q26	Inline
Keymed	Guide Rmb850mn sales for stapokibart in 2026	Up	CM512 could emerge as credible successor to the stapokibart franchise; Sone-Ve's value emphasizing 1L GC and peri-operative settings	1H26	Beat
Ocumension	Corporate-level profitability in FY26	-	Steady progress towards profitability; eyes on OT-101 ph3 data / Youshiying local supply	1H26	Miss
CARsgen	200 orders for satri-cel in FY26	New	Narrowing loss despite slower ramp-up of zevor-cel; YE readouts of off-the-shelf CAR-Ts as focus	1H26	Miss
Antengene	Profitability in FY26	-	1H profitability driven by license income; eyes on ESMO for ATG-022 updates	1H26	Inline
Jacobio	-	n.a.	1H26 in-line with strengthened cash; Pan-RAS profile maintained in larger sample	1H26	Inline
Ascletis	-	n.a.	Concentrated focus on metabolic franchise with cash runway through ASC30 filing	1H26	Miss
Abbisko	-	n.a.	1H in-line with strengthened cash; Key readouts concentrated in POC pipeline	1H26	Inline
CStone	-	n.a.	1H beat with continued R&D investment; eyes on ESMO as CS2009 strengthening its profile	1H26	Beat
Impact	Rmb200mn for senaparib for FY26	-	1H in-line with senaparib on-track; Pipeline updates on IMP1734 and dpADC/degrader	1H26	Inline
Betta Pharma	Management maintained its FY26 guidance of Rmb4.0bn revenue and Rmb500-600mn net profit	-	Pan-RAS as the company's important pipeline value driver; Management remains constructive on EYP-1901	2Q26	Mixed
Retail pharmacy					
Yifeng	Open 500 new directly operated stores and 1,000 franchised stores in 2026, and acquire 500 stores; SSSG to reach 5% in FY26	Down	Store count improving with SSSG turn positive since 2Q25	1H26	Miss
Dashenlin	Open 500 new directly operated stores and 2,000 new franchised stores by 2026, and hopes to complete 500 new acquisitions.	-	Better-than-expected GPM to mitigate industry headwinds	1H26	Beat
LBX	Target of adding 300-400 self-operated stores, 1200 franchised stores, and 300 acquired stores in 2026	Down	SSSG turned positive in 4Q25 and the trend is sustainable	1H26	Beat
Healthcare Services					
Aier	2H26 will be better than 1H26	n.a.	Refractive surgery pricing trend, cataract IOL VBP, going global	1H26	Miss
Hygeia	-	-	Earnings came higher on better-than-feared GPM despite the revenue miss	1H26	Beat
Gushengtang	-	-	Resilient patient traffic; overseas expansion and shareholder returns on track	1H26	Miss
Jinxin Fertility	-	-	1H26 stabilizing; shareholder returns reiterated, continute to monitor the sustainability of volume and pricing traction across major regions	1H26	Inline
Topchoice	Full year guidance maintained (Previously: 30% y/y revenue growth. Implant dentistry volume at 200k, orthodontics volume at 50k cases, and "Dandelion Program" hospitals revenue growth at 48% y/y)	-	Stabilizing operational trend; monitoring the pace of summer/2H demand recovery, particularly in higher-value dental procedures	2Q26	Inline
Kingmed	FY26 revenue growth at 6%	New	Diagnostic service price unification should be milder than previous estimation	1H26	Miss
Distributor					
CR Pharm	Guidance not mentioned	n.a.	Synthetic biology increasingly positioned as a long-term driver	1H26	Inline
Sinopharm	Guidance not mentioned	n.a.	Retail business well positioned for industry trend	2Q26	Inline


Source: Company data, Data compiled by Goldman Sachs Global Investment Research

Performance: Offshore HC outperformed versus index YTD, led by CDMO/CRO

Exhibit 4: Offshore HC outperformed YTD, led by CRO/CDMO and Biotech


The composite for each sector includes GS and non-GS covered stocks listed in A/H/ADR (ex dual listed). As of Sep 7, 2026

Sector	2020	2021	2022	2023	2024	2025	3Q25	4Q25	1Q26	2Q26	Jul-26	Aug-26	YTD	Valuation (PE) Now	5y avg	%tile	3y avg	%tile	Sales CAGR (24-26E)	NI CAGR (24-26E)	Cons NI Revision (FY26) 3M	6M
CSI 300	24%	-1%	-22%	-14%	13%	21%	17%	0%	-3%	8%	-6%	0%	-2%	15x	13x	89%	12x	94%				
MXCN	24%	-20%	-24%	-17%	18%	32%	18%	-6%	-10%	-10%	11%	0%	-12%	11x	11x	61%	11x	74%				
Onshore	70%	-8%	-19%	-9%	-12%	5%	15%	-12%	-3%	-13%	13%	1%	-5%	21x	23x	41%	20x	60%	7%	14%	1%	-4%
Offshore	72%	-22%	-16%	-20%	-10%	54%	38%	-19%	-1%	-14%	13%	12%	5%	17x	18x	57%	15x	71%	7%	21%	5%	4%
CRO/CDMO	152%	7%	-33%	-32%	-26%	56%	67%	-20%	2%	10%	10%	23%	49%	22x	36x	31%	22x	48%	22%	48%	11%	13%
Biotech	83%	-10%	-20%	5%	0%	67%	33%	-21%	3%	-16%	14%	11%	7%	-	-	-	-	-	33%	-	-	-
Pharmacy	72%	-20%	9%	-21%	-31%	-6%	-4%	-6%	3%	-21%	24%	-1%	1%	15x	20x	17%	17x	26%	7%	18%	-1%	-5%
Diagnostic	73%	-20%	-25%	-13%	-22%	-1%	9%	-10%	1%	-17%	9%	2%	-8%	14x	16x	48%	14x	55%	0%	10%	-1%	-10%
Distributor	-16%	-10%	28%	-6%	12%	-13%	0%	-1%	1%	-16%	10%	-4%	-11%	9x	8x	59%	8x	57%	6%	9%	-3%	-2%
Pharma	32%	-22%	-12%	-1%	-4%	31%	26%	-14%	-3%	-19%	13%	-1%	-12%	21x	20x	69%	19x	73%	10%	16%	-1%	-5%
TCM	27%	31%	-14%	0%	-7%	-12%	-1%	-4%	-4%	-17%	17%	-6%	-14%	16x	20x	4%	18x	7%	5%	6%	-10%	-15%
Hospital	107%	-24%	-5%	-31%	-20%	-15%	0%	-10%	-5%	-17%	11%	-5%	-17%	23x	40x	26%	27x	40%	7%	6%	-6%	-15%
MedDevice	91%	-12%	-18%	-18%	-14%	-9%	16%	-16%	-7%	-21%	12%	0%	-17%	21x	26x	39%	21x	60%	11%	12%	-6%	-18%
Plasma/vaccine	107%	-15%	-29%	-4%	-38%	-20%	4%	-10%	-8%	-22%	11%	4%	-20%	-	-	-	-	-	-17%	-7%	-23%	-54%
HealthcareTech	127%	-60%	-2%	-35%	-17%	61%	39%	-19%	-11%	-35%	18%	-9%	-37%	26x	123x	11%	74x	18%	22%	-	-	-



Source: Bloomberg, data compiled by Goldman Sachs Global Investment Research

Exhibit 5: CRO/CDMO and Biotech outperformed other sectors
As of Sep 7, 2026



Source: Bloomberg, data compiled by Goldman Sachs Global Investment Research

Exhibit 6: Genscript led in 1-month performance on interest in AIDD, versus laggards such as Betta and Livzon
For GS coverage. As of Sep 7, 2026

1M Perf Leaders


BBg Code	Company Name	Mkt cap (US$, mn)	Abs perf 1M	Abs perf 6M
1548 HK	Genscript Biotech	8,781	35%	174%
1167 HK	Jacobio Pharma	650	27%	(14%)
2268 HK	WuXi XDC	11,119	17%	26%
9688 HK	Zai Lab (H)	2,876	17%	33%
2616 HK	CStone Pharma	1,165	16%	(17%)
1952 HK	Everest Medicines	1,431	15%	(15%)
ZLAB US	Zai Lab (ADR)	2,849	12%	38%
300760 CH	Mindray	30,679	12%	(6%)
1093 HK	CSPC Pharma	14,232	11%	7%
6821 HK	Asymchem (H)	6,178	11%	58%

1M Perf Laggards

BBg Code	Company Name	Mkt cap (US$, mn)	Abs perf 1M	Abs perf 6M
300558 CH	Betta Pharma	3,047	(31%)	10%
1513 HK	Livzon Pharma (H)	2,423	(21%)	(27%)
600276 CH	Hengrui Medicine	45,514	(15%)	(17%)
6996 HK	Antengene	308	(15%)	(18%)
2171 HK	CARsgen Therapeutics	973	(14%)	(19%)
867 HK	China Medical System	3,435	(12%)	(16%)
2186 HK	Luye Pharma Group	856	(12%)	(23%)
000513 CH	Livzon Pharma (A)	3,718	(11%)	(22%)
688235 CH	BeOne (A)	54,142	(11%)	11%
1789 HK	AK Medical	664	(11%)	(17%)

Source: Bloomberg, data compiled by Goldman Sachs Global Investment Research

Exhibit 7: China onshore HC trading at 21.5x
12m fwd aggregated P/E (as of Sep 7, 2026)



Source: Bloomberg, Goldman Sachs Global Investment Research

CDMO: Robust new order/ backlog growth in 2Q26

Exhibit 8: New order momentum continued in 2Q, with signs of early-stage recovery
CDMO new order and backlog growth summary

Note: 1) * for continuing operations; 2) new order based on backlog within 3 years for WuXi Biologics; 3) cal. denotes new order based on calculation, rest per company
CCY = constant currency, ex-FX impact


New order growth, y/y	2023	2024	1Q25	2Q25	3Q25	4Q25	2025	1Q26	2Q26
WuXi AppTec	-1% (cal.)	30%*	25%*	12%*	18%*	n.a.	n.a.	ccy 25%*	1H26 40%* (ccy 45%)
WuXi Biologics	15% (cal.)	13%-15%*	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
WuXi XDC	n.a.	75% (cal.)	n.a.	1H25 48%	n.a.	2H25 29% (cal.)	41%	n.a.	1H26 47% (cal.)
Asymchem	n.a.	20%	Maintain the momentum	n.a.	9M25 double digit	n.a.	n.a.	n.a.	1H26 55%
Tigermed	-19%	7%	20%	Aug YTD mid teens	9M25 mid teens	n.a.	21%	High double digit	1H26 30%+ y/y
Pharmaron	n.a.	>20%	10%	1H25 10%	9M25 13%	n.a.	14%	30%	1H26 30%
Lab service	n.a.	15%	10%	1H25 10%	9M25 12%	n.a.	12%	20%	1H26 20%
CMC	n.a.	35%	10%	1H25 20%	9M25 20%	n.a.	13%	50%	1H26 50%

Note:1) * for continuing operations; 2) calculated based on disclosed backlog for WuXi AppTec, WuXi Bio (backlog within 3 years), and WuXi XDC;
3) per company for Asymchem; 4) WuXi XDC 1H26 growth on service backlog

Backlog growth, y/y	2023	2024	1Q25	2Q25	3Q25	4Q25	2025	1Q26	2Q26
WuXi AppTec	7%	47%*	47%*	1H25 37%*	9M25 41%*	n.a.	29%* (ccy 34%*)	24% (ccy 29%)*	1H26 25%* (ccy 30%)
WuXi Biologics	6%	11%*	n.a.	1H25 29%*	n.a.	n.a.	24%*	n.a.	1H26 24%*
WuXi XDC	82%	71%	n.a.	1H25 58%	n.a.	n.a.	50%	n.a.	1H26 50%
Asymchem	n.a.	>20%	n.a.	n.a.	n.a.	n.a.	32%	n.a.	1H26 54%
Chemical macromolecule	n.a.	n.a.	n.a.	1H25 90%	n.a.	n.a.	128%	n.a.	1H26 163%
Biological macromolecule	n.a.	n.a.	n.a.	1H25 60%	n.a.	n.a.	56%	n.a.	1H26 89%
Drug products	n.a.	n.a.	n.a.	1H25 35%	n.a.	n.a.	49%	n.a.	1H26 31%

Source: Company data, Goldman Sachs Global Investment Research


Exhibit 9: Chinese CRO/CDMOs have been relatively less sensitive to geopolitical uncertainty than last year



Source: Company data, Reuters, Congress.gov


Overseas funding momentum saw minor slow down, as domestic funding stayed relatively muted

Exhibit 10: The momentum of US public HC funding declined since June...
Equity funding for US healthcare (IPOs/FOs) by month




Source: Wind

Exhibit 11: ... similar for global private biotech funding
Global private biotech funding by month




Source: Pharmcube

Exhibit 12: China public HC funding remained small despite short recovery in July
Equity funding for China healthcare (IPOs/FOs) by month



Source: Wind

Exhibit 13: ... versus relatively stable amount for China private biotech funding
China private biotech funding by month



Source: Pharmcube


Biotech licensing deal momentum continued

Exhibit 14:
Top 10 deals (by deal size) of 3Q26 as of Sep 4

Date	Transferor	Transferee	Assets	Total Payment (US$mn)	Upfront (US$mn)	Target	R&D Stage	Territory	MoA / Modality
2026-07-14	Hansoh	Avere	HS-20118 (AVR-001)	2,300	120	IL-23R	Phase II	Full Rights: US;EU;JP;Other	Small molecule
2026-07-08	Chia Tai Tianqing	AstraZeneca	TQC3721	2,100	200	PDE4; PDE3	Phase III	Full Rights: HK, MO and TW;US;EU;JP;Other | R&D Rights: Global	Small molecule
2026-08-04	Alphamab	Pathos	JSKN-016	2,093	125	HER3; TROP2	Phase III	Full Rights: US;EU;JP;Other	ADC; BsAb
2026-07-02	CSPC	AstraZeneca	siRNA candidates	1,770	30	not available	PreClinical	R&D Rights: Global | Full Rights(Option): US;EU;JP;Other	siRNA
2026-08-26	Haisco	Sentivera	HSK60002	1,536	76	STAT6	Phase I	Full Rights: US;EU;JP;Other	Small molecule
2026-09-01	Simcere	Roche	SIM0660	1,530	75	CD3; CD19; CD79a	PreClinical	Full Rights: Global	TsAb
2026-07-13	Dizal	AstraZeneca	sunvozertinib	1,500	600	EGFR & HER2 exon 20	Approved	Commercialization Rights: Global | R&D Rights: Global	Small molecule
2026-07-14	Innovent	Spero	IBI355	1,100		CD40L	Phase I	Full Rights: US;EU;JP;Other	mAb
2026-08-28	DualityBio	Genentech	DUPAC ADC program	1,045	45	not available		R&D Rights: Global | Full Rights: Global	ADC
2026-08-11	Gan Lee Pharma	Menarini	bofanglutide	821	70	GLP-1R	Phase III	R&D Rights: EU | Commercialization Rights: EU	Small molecule

Source: Pharmcube


Exhibit 15: 50+ China-sourced BD deals each quarter for the past three quarters
Number of in-license/out-license BD and M&A for China Biotech, as of Sep 4, 2026



Source: PharmCube, data compiled by Goldman Sachs Global Investment Research

Exhibit 16: Total deal sizes surpassed US$100bn in 1H26

Total deal value of out-license BD and company acquisition activities for China Biotech (FY2022-2Q26)



Source: PharmCube, data compiled by Goldman Sachs Global Investment Research

Biotech & Pharma Catalysts

Exhibit 17: Catalyst table for China biotech

As of Sep 7, 2026

Date	2H26	1H27	2H27 and beyond
Conference	WCLC (Sep); ASN (Oct); ESMO (Oct); SITC (Nov); ACR (Nov); AHA (Nov); ASH (Dec); SABCS (Dec); ESMO-IO (Dec)		
Abbisko	Pimicotinib (CSF-1R): US approval in TGCT (11/13/2026) Irpagratinib (FGFR4): preliminary ph2 data in 1L FGF19+ HCC (triplet) ABSK043 (oral PD-L1): ph2 12m PFS data in 1L EGFRm NSCLC (+furmonertinib) ABSK061 (FGFR2/3): preliminary ph2 data in 1L GC and in ACH	Irpagratinib (FGFR4): Data of pivotal China trial in 2L+ FGF19+ HCC, ABSK131 (PRMT5-MTA): Ph1 data	Irpagratinib (FGFR4): China NDA in 2L HCC (2H27), China approval (2028), initiate ph3 MRCT in 1L FGF19+ HCC (+atezo+/-beva)
Akeso	AK112: primary PFS / interim OS readout in sq-NSCLC of HARMONi-3 (SMMT) AK112: OS data of AK112-303/HARMONi-2 trial in 2026 (WCLC26) AK112: FDA approval in 2L EGFRmut NSCLC (PDUFA 11/14/2026)	AK112: primary PFS analysis for misq-NSCLC and and interim OS analysis in sq-NSCLC of HARMONi-3 in 1H27 (SMMT)	
Antengene	ATG-022 (CLDN18.2 ADC): ph2 data readout in 1/2L GC (4Q26), ph1 CLINCH survival data / non-GI data (ESMO), initiate ph3 trial in 3L+ GC TCE: potential BD deals ATG-037 (CD73): combo data with PD-1/VEGF in CPO-resistant melanoma (ESMO)	ATG-022 (CLDN18.2 ADC): potential BD (mid-27)	
Ascletis Pharma	ASC30 (oral GLP-1): topline data readouts from the US 13-week ph2 study in T2D (3Q26) ASC30 (oral GLP-1): Patient enrollment for US/EU ph3 trial in obesity		ASC30 (oral GLP-1): topline data expected 3Q28
BeOne Medicines	BTK-CDAC: AA submission in R/R CLL (if ph2 data support) Sonrotoclax (BCL2): uMRD data of ph3 CELESTIAL trial in 1L CLL (check) Brukinsa: 1L MCL submission Pirto (read-across): potential ph3 update for BRUIN-313/314 BGB-B2033 (GPC3/41BB): initiation of ph3 trial in 2L+ HCC, initiation of potential pivotal ph2 trial in GI, ph1 DO and DE update (ESMO26) BG-C9074 (B7H4 ADC): initiation of ph3 trial in 1L OC maintenance in 4Q26 Tevimbra: FDA approval in 1L HER2+ GEA IND of hema NMEs (TsAbs, CD19/δT cell) POC data for CEA ADC and PRMT5 in 2H26 (ESMO26)	BTK-CDAC: potential FDA approval in R/R CLL; + sonro ph3 initiation in R/R CLL (2Q27) Sonrotoclax (BCL2): triplet ph3 initiation in 2L+ t(11;14) MM (postponed from 2H26) BGB-58067 (PRMT5): initiation of potential ph3 in NSCLC BG-C477(CEA ADC): initiation of potential ph3 in NSCLC	Sonrotoclax (BCL2): ph3 readout in TNCLL (ZS vs. VO) BGB-B2033 (GPC3/41BB): initiation of pivotal trial in 1L HCC (+tisle+beva; 2H27)
Carsgen	CT041 (CLDN18.2 CAR-T): IIT data update in adj. GC at ESMO CT0596 (allogeneic BCMA CAR-T): IIT data update by YE26, initiate ph1b by YE26 CT1190B (allogeneic CD19/CD20 CAR-T): IIT data update at ASH, initiate China ph1, file IND in the US KJ-C2529 (in-vivo CD19/CD20 CAR-T): IIT data update YE26		CT0596(allogeneic BCMA CAR-T): initiate pivotal ph2 trial CT1190B (allogeneic CD19/CD20 CAR-T): initiate pivotal ph2 trial KJ-C2529 (in-vivo CD19/CD20 CAR-T): clincal data readout in 2027 Potential IIT for other early pipeline programs (e.g. allogeneic NKG2DL / CLDN18.2; CLL1)
CStone	CS2009 (PD-1/VEGF/CTLA4 tsAb): ph2 combo data update in 1L/2L+ NSCLC and ph1/2 data in mCRC (ESMO); FDA alignment on ph3 MRCT for 2L NSCLC / 1L NSCLC and 1L mCRC (PD-L1>=50%) (possible initiation in 4Q26), potential BD deal	CS2009: ph2 combo data update in 2L NSCLC (+docetaxel) and mono data update in 1L NSCLC (PD-L1>=50%) (1Q27), possible ph3 initiation ADC combo in 1L NSCLC in 2Q27	
Everest	EVER001 (BTK): BD deal with Travere. Initiated ph2 basket trial for broad indications (IgAN/MCD/FSGS/LN) Etripamil: potential NMPA approval in PSVT (3Q26)	EVM18 (in-vivo CAR-T): potential IIT data EVM16(mRNA cancer vaccine): IIT to data in 2Q27 / FDA IND in 1H27 LNZ100: China approval in presbyopia 1H27 Lerodalcibep-lga: potential NMPA approval in hypercholesterolemia	EVM14 (mRNA cacner vaccine): potential IIT data MT1013: potenbal NMPA approval in 2028 3-5 BD deals each year. Rmb10bn / Rmb15bn revenue by 2028/2030
GenFleet	GFH276 (pan-RAS): Ph1 readout at ESMO GFH375 (KRAS G12D): Ph1b/2 readout (+cetuximab) in PDAC / CRC at ESMO; Global Ph1/2 readout in solid tumors by Verastem GFS784 (pan-RAS ADC): IND approval	GFH276 (pan-RAS): Initiation of China Ph3 registrational trial in 2L+ PDAC GFH375 (KRAS G12D): Ph1b/2 readout (+chemo) in 1L PDAC; FPI in global ph3 TARGET-D trials (subject to FDA); Initiation of China pivotal trial in 3L+ CRC ERAS-0015 (read-across): ph1/2 dose expansion data (mono) and dose escalation data (+sarilumumab)	GFH276 (pan-RAS): Initiation of Ph3 registrational trial in 1L PDAC GFH375 (KRAS G12D): Ph3 readout in 2L+ PDAC (China trial), file NDA in China GFS784 (pan-RAS ADC): clincal data debut
Henlius	Serplulimab: data readout for US bridging study in SCLC at ESMO HLX43: incremental data updates on GC at ESMO		

Key catalysts highlighted in red.

Source: Company data, data compiled by Goldman Sachs Global Investment Research

Exhibit 18: Catalyst table for China biotech (cont'd)

As of Sep 7, 2026

Date	2H26	1H27	2H27 and beyond
IMPACT	**Senaparib (PARP1/2):** EU approval in 1L OC **IMP1734 (PARP1):** ph1/2 data in Pca (+abiraterone) (ESMO) **IMP1707 (PARP1):** ph1 mono data in solid tumors (ESMO) **IMP9064 (ATR):** ph1b data in PARP-treated OC (+senaparib)	**IMP9064 (ATR):** ph2 mono data in solid tumors **IMP1734 (PARP1):** ph2 mono data in BC and other tumors	**IMP1734 (PARP1):** determine the next steps for more detailed indications (2H27) **Saruparib (AZD5305, PARP1):** Ph3 data in 1L mCSPC (EvoPAR-Prostate01)
InnoCare	Potential BD deal for Mesutoclax; phase 1 data from ICP-538 (VAV1 molecular glue degrader) and ICP-054 (oral IL-17 inhibitor)		
Innovent Biologics	**IBI363 (PD-1/IL-2α)**: ph1b POC data in 1L CRC/1L NSCLC; initiate global ph3 trial in IO-resistant nsq-NSCLC **IBI363 (PD-1/IL-2α):** Pivotal ph2 data in IO-naive melanoma (vs. Keytruda); 1L GC data (ESMO) **Next-gen ADC FIH data:** IBI3001 (EGFR/B7H3) at ESMO **IBI343 (CLDN18.2 ADC)** 3L+ GC ph3 interim results (CN/JP) **IBI354 (HER2 ADC)**: POC data in neoadj. BC **Mazdutide(GCG/GLP-1)**: GLORY-3 readout (vs. sema in obesity) **IBI3042** (weekly oral GLP-1), ph1 in obesity **IBI324** (VEGF/Ang2), global ph3 initiation in DME and wAMD **IBI356** (OX40L): ph2 initiation in AD IBI3003 (GPRC5D/BCMA/CD3): data update in 4L+ MM **IBI3002** (TSLP/IL-4Rα): ph1 data in asthma SYCUME® (IGF-1R): ph3 readout for inactive TED	**IBI3032** (oral GLP-1): initiate global ph2 trial in obesity **IBI363** (PD-1/IL-2α): initiate global ph3 trials in 1L NSCLC / 1L CRC; first NDA in melanoma **Next-gen ADC FIH data:** IBI3005 (EGFR/HER3) / IBI3014 (PD-L1/TROP2) / IBI3020 (CEACAM5 dpADC)	Rmb20bn in revenue (Rmb4-5bn for mazdutide) for FY2027 Rmb35-40bn total revenue in FY2030
Jacobio Pharma	**JAB-BX467** (HER2-STINGi ADC), submit IND in 2H26 **JAB-BX600** (EGFR-KRAS G12Di tADC): submit IND in 2H26	**JAB-23E73** (pan-KRAS): potential ph1 combo data in 1L PDAC (+AGchemo)	**JAB-23E73** (pan-KRAS): initiation of global ph3 trial by AZN Pan-RASi tADC: IND in 2H27
Kelun Biotech	**sac-TMT**: 1) 1L EGFRwt NSCLC with PD-L1 TPS<1 - potential data sharing at ESMO2026; 2) China ph3 in HR+/HER2- BC OS interim; 3) potential FDA BLA in EC (YE26) **SKB571** (BsADC): potential ph1/2 data readout (Gse) **Dato-DXd** (read-across): 1) ph3 readouts in 1L NSCLC (AVANZAR, TL-07, TL-08); 2) ph3 readout of TL-15 (2L EGFRm NSCLC)	**sac-TMT**: potential FDA approval in EC **sac-TMT**: Global ph3 data - 1) 2L+ endometrial cancer (TroFuse-005), 2) 3L+ GEA (TroFuse-015). **sac-TMT**: Interim OS for OptiTROP-Lung05 (1L NSCLC PD-L1>1%) at ASCO27 **SKB105 (ITGB6 ADC):** ph1/2 data (mono) in 1Q27 Firm-level break-even in 2026/27 **A400 (RET):** China market launch	**sac-TMT:** Global ph3 data - 1) 3L+ EGFRmut NSCLC (TroFuse-004), and 2) chemo-naive HR+/HER2- BC (TroFuse-010). **SKB105 (ITGB6 ADC):** ph1/2 combo data (+PD-1/VEGF) by YE27
Keymed	AZD0901 to file BLA with FDA and release global phase 3 data on GC in ESMO	CM336 to initiate global phase 3 trials by Gilead	CM512 phase 2 data on asthma and COPD
Legend	**Carvykti**: PFS data in CARTITUDE-5 (late-26 / early-27) **Carvykti**: long-term data of CAR-4 **LB2501** (CD19/CD20 in-vivo): FDA IND filing	Company-level profitability for FY26	**Carvykti**: PFS data in CARTITUDE-6 (2029)
Ocumension	**OT101 (low-dose atropine):** Ph3 data readout expected in October **OT101**: potential global out-licensing deal **OT101**: NDA filing in US (on rolling basis) / CN in 2H26 Yutiq: potential approval for domestic supply	NI break-even for FY26	**OT-802** (for presbyopia): potential ph3 data readout
Zai Lab	**ZL-1310 (DLL3 ADC)**: ph1 dose escalation data for 1L SCLC (+atezolizumab+-chemo) at ESMO26; initiation of pivotal trial in 1L SCLC / NEC **KarXT**: readout of ph3 ADEPT-2 trial in ADP (YE26); NRDL negotiation (YE26) **Efgartigimod:** Ph3 data in myositis **Optune** (TTF): China approval in pancreatic cancer **ZL-1503 (IL-13/IL-31)**: FIH SAD data in healthy volunteers (2H26) IND for ZL-1222 (PD-1/IL-12), ZL-1311 (MUC17/CD3)	**ZL-1310 (DLL3 ADC)**: ORR data of ph3 trial in 2L+ SCLC; complete enrollment for ph3 DLLEVATE trial ZL-6201 (LRRC15 ADC): ph1 data in sarcoma / selected tumors **ZL-1503 (IL-13/IL-31):** MAD data in patients **Efgartigimod:** Ph3 data in Sjogren's syndrome **VRDN-003 (IGF-1R):** China NDA in TED	**Zoci (DLL3 ADC):** interim analysis of ph3 DLLEVATE trial, potential filing for AA in 2027

Key catalysts highlighted in red.

Source: Company data, data compiled by Goldman Sachs Global Investment Research


Exhibit 19: Catalyst table for China pharma
as of Sep 7, 2026

Date	2H26	2027 and beyond
CSPC Pharma	Phase II data for the EGFR ADC combined with PD-1 in first-line EGFRwt NSCLC (WCLC); PD-1/IL-15: Phase I pan-tumor data (ESMO); B7-H3 ADC: Phase I breast cancer data (ESMO)	
Gan & Lee	Potential approval in EU for insulin aspart & lispro	Potential approval of GZR18; Potential approval for insulin glargin, aspart, and lispro in the US
Hansoh	Key data readout in 2026 include: 1) phase 3 data of B7-H3 ADC on SCLC (WCLC) and osteosarcoma (ESMO); 2) phase 3 data of oral TYK2 on psoriasis; 3) phase 2 data of HS-10382 (Bcr-Abl); and 4) first-in-human data of EGFR/cMET bispecific ADC, HS-10504 (next-generation EGFR TKI, C797S), HS-20118 (oral IL-23 peptide) and HS-10501 (oral GLP-1 small molecule)	
Hengrui	SHR-1139 (IL-23p19/IL-36): Phase II psoriasis/IBD data in 2H26; GLP-1 franchise: additional HRS9531, HRS-7535, HRS-4729 data are expected at EASD; HER3 ADC: phase 3 data on NSCLC (ESMO); Lp(a) siRNA: phase 1 data at AHA	
Huadong		Potential approval for QS005
Nhwa		
Sino Biopharma	phase 2 data of CCR8 mAb for PC and GC on ESMO	
Tonghua Dongbao		Potential approval for insulin glargin, aspart, and lispro in the US
United Lab	Sequential recovery of API price; PYY (UBT37034) is expected to deliver Phase I data	
Zhifei	Potential approval for PCV15	

Source: company data, Data compiled by Goldman Sachs Global Investment Research

Innovative drugs are becoming the major contributor for Pharma; sustained GM pressure for distributors

Exhibit 20: Hansoh has the largest exposure to innovative drug business among the top pharma names in our coverage
1H26 Revenue breakdown for top pharma companies in China in terms of generic/innovative drug sales contribution



*CSPC's finished drug portfolio

Source: Company data, Pharmcube, Data compiled by Goldman Sachs Global Investment Research

Exhibit 21: Comparison of growth outlook and valuation for covered pharma companies


	Company Name	Mkt Cap	Sales yoy		Net profit yoy		PE		PEG		EV/EBITDA		CROCI		ROE		ROA	
		Rmb, mn	2026E	2027E	2026E	2027E	2026E	2027E	2026E	2027E	2026E	2027E	2026E	2027E	2026E	2027E	2026E	2027E
1177.HK	Sino Biopharm	88,874	13.1%	5.7%	121.9%	3.9%	17.1	16.5	0.1	4.2	8.5	8.4	9.9%	8.9%	11.3%	10.1%	6.1%	5.8%
	vs. peers avg		▲	▲	▲	▲												
1093.HK	CSPC Pharma	95,506	24.8%	0.5%	102.9%	-9.1%	12.1	13.3	0.1	-1.5	8.5	9.0	12.8%	10.0%	20.8%	16.7%	14.7%	12.7%
	vs. peers avg		▲	▼	▲	▼												
3692.HK	Hansoh Pharma	183,586	13.1%	14.4%	25.3%	3.2%	26.4	25.6	1.0	8.0	22.8	19.2	11.9%	11.9%	18.5%	17.0%	15.7%	14.6%
	vs. peers avg		▲	▲	▼	▲												
1276.HK	Hengrui Pharma (H)	305,435	5.1%	11.0%	12.8%	12.5%	35.1	31.2	2.7	2.5	23.8	20.6	10.6%	10.8%	13.3%	13.4%	11.3%	11.4%
	vs. peers avg		▲	▲	▲	▲												
2196.HK	Fosun Pharma (H)	23,055	0.5%	1.1%	7.3%	9.4%	9.8	9.0	1.3	1.0	-136.3	-196.4	1.5%	1.6%	5.6%	5.8%	2.9%	3.0%
	vs. peers avg		▲	▼	▲	▼												
0867.HK	China Medical System	23,055	15.2%	12.6%	29.6%	12.3%	11.9	10.6	0.4	0.9	7.1	5.9	8.9%	9.9%	10.6%	11.2%	9.4%	9.8%
	vs. peers avg		▲	▲	▲	▲												
1513.HK	Livzon Pharma (H)	16,258	-14.9%	1.5%	-9.6%	-5.6%	8.9	9.4	-0.9	-1.7	3.4	3.8	6.8%	6.0%	11.4%	10.2%	7.3%	6.7%
3933.HK	United Labs	13,160	-6.3%	0.9%	-68.3%	36.2%	19.9	14.6	-0.3	0.4	5.6	4.8	2.1%	2.0%	3.7%	4.8%	2.4%	2.8%
1530.HK	3SBio	35,276	-48.3%	9.1%	-71.6%	32.8%	14.6	11.0	-0.2	0.3	8.5	7.6	5.6%	6.1%	7.6%	9.2%	6.2%	7.6%
2186.HK	Luye Pharma	5,743	-1.9%	6.1%	7.2%	-10.2%	8.7	9.6	1.2	-0.9	6.4	5.9	1.7%	2.3%	3.5%	3.1%	2.2%	2.0%
HK-listed Pharma Peers Average			**0.0%**	**5.7%**	**14.3%**	**7.8%**	**15.0**	**13.7**	**0.7**	**1.3**	**9.5**	**8.5**	**7.0%**	**6.8%**	**10.1%**	**9.6%**	**7.5%**	**7.3%**

▲ growth higher than peer average
▼ growth lower than peer average

PE/PEG lower than average
PE/PEG higher than average


Source: Bloomberg, Goldman Sachs Global Investment Research

Exhibit 22: Gross margin was under sustained pressure for distributors
Gross margin of top 3 healthcare distributors in China (2019-2026E)



Source: Company data, Goldman Sachs Global Investment Research

Exhibit 23: Favourable financing policy in China could benefit distributors
Financing costs as percentage of revenue for top healthcare distributors in China (2019-2026E)




Source: Company data, Goldman Sachs Global Investment Research



MedTech: Hospital equipment bidding: Weakness continues

Exhibit 24: We saw an inflection point for public hospital bidding data in June...


Procurement value



Source: Joinchain

Exhibit 25: ...With patient monitor/CT/MRI/DSA still showed strong growth momentum in Aug


Procurement value y/y growth



Source: Joinchain

Service: Reimbursement pressure persists; going-global remains the key growth driver


Exhibit 26: Higher revenue exposure to reimbursement fund for Hygeia and Gushengtang versus peers



For Gushengtang, c.30% from social pooling account and c.10% from individual account. Data is as of latest reported.

Source: Company data, Data compiled by Goldman Sachs Global Investment Research

Exhibit 27: Going global is becoming a key growth driver




2Q26 for SNIBE, and 1H26 for the rest

Source: Company data, Data compiled by Goldman Sachs Global Investment Research

Valuation: Onshore/offshore HC trading multiples experienced short-term decline followed by quick recovery

Exhibit 28: Onshore and offshore HC trades both recovered to above 3y avg
Healthcare P/E (aggregated); as of Sep 7, 2026




Source: Bloomberg, Data compiled by Goldman Sachs Global Investment Research

Exhibit 29: Onshore/offshore HC quickly recovered from low point in June
Aggregated 12m fwd P/E; as of Sep 7, 2026




Source: Bloomberg

Exhibit 30: Onshore/offshore HC trades at 2.0x/1.6x PS
Healthcare PS (aggregated); as of Sep 7, 2026



Source: Bloomberg

Exhibit 31: The trading multiples of Onshore/Offshore are at the medium range
12m fwd P/E (2022-2026), ex A-share if dual listed; as of Sep 7, 2026




Source: Bloomberg

Upward revision for CRO/CDMO in the last 3M

Exhibit 32: CRO/CDMO see major revision with robust new order growth in the last 3M...


Earnings revisions on an aggregate basis, as of Sep 7, 2026



Source: Bloomberg, Data compiled by Goldman Sachs Global Investment Research

Exhibit 33: ...as in the last 6M

Earnings revision on an aggregate basis, as of May 13, 2025




Source: Bloomberg

Trading activities: Onshore trading value continued trending high; expanding interest in CRO/CDMO in both onshore and offshore

Exhibit 34: Onshore trading on the rise again since June ...


Average trading value by month. As of Sep 7, 2026



Source: LSEG Datastream

Exhibit 35: ...with expanding interest in CRO/CDMO


Average trading value by month. As of Sep 7, 2026



Source: LSEG Datastream

Exhibit 36: Offshore trading volume remained stable...


Average trading value by month. As of Sep 7, 2026



Source: LSEG Datastream

Exhibit 37: ...with interest in Biotech remaining high, while CRO/CDMO is quickly gathering more attention

Average trading value by month. As of Sep 7, 2026



Source: LSEG Datastream

Exhibit 38: CRO/CDMO companies dominated onshore and offshore trading in last 1 month

As of Sep 7, 2026

Most traded in ADTV (US$ mn)						
	Ticker	Company name	Sub-sector	Mkt cap (US$ mn)	Last M	vs 12M avg
Onshore						
1	603259 CH	WuXi Apptec	CRO/CMO	69,143	**1,512**	97%
2	600276 CH	Hengrui	Pharma	45,522	**667**	24%
3	300759 CH	Pharmaron	CRO/CMO	10,377	**519**	168%
4	600664 CH	Harbin Pharma	Pharma	3,002	**482**	430%
5	002437 CH	Harbin Gloria Pharmaceutic	Pharma	1,312	**359**	470%
Offshore						
1	2269 HK	WuXi Biologics	CRO/CMO	25,812	**279**	72%
2	2359 HK	WuXi Apptec	CRO/CMO	69,143	**191**	95%
3	1801 HK	Innovent	Biotech	22,625	**183**	17%
4	1548 HK	Genscript Biotech Corp	Biotech	8,675	**179**	381%
5	9926 HK	Akeso Inc	Biotech	11,352	**147**	5%

Source: LSEG Datastream

Exhibit 39: RNA cancer vaccine has become a topic for trading in the last month among offshore HC


As of Sep 7, 2026

More active trading ADTV US$mn						
	Ticker	Company name	Sub-sector	Mkt cap (US$ mn)	Last M	vs 12M avg
Onshore						
1	002437 CH	Harbin Gloria Pharmaceutic-A	Pharma	1,312	359	**470%**
2	600664 CH	Harbin Pharma	Pharma	3,002	482	**430%**
3	600479 CH	Zhuzhou Qianjin Pharmaceut-A	Pharma	1,016	66	**342%**
4	688185 CH	Cansino (A)	Plasma/vaccine	1,644	87	**248%**
5	300725 CH	Pharmablock Sciences Nanji-A	CRO/CMO	1,484	202	**218%**
Offshore						
1	6185 HK	Cansino (H)	Plasma/vaccine	1,644	34	**407%**
2	1548 HK	Genscript Biotech Corp	Biotech	8,675	179	**381%**
3	1952 HK	Everest Medicines Ltd	Biotech	1,404	66	**207%**
4	3759 HK	Phamaron	CRO/CMO	10,377	44	**110%**
5	2359 HK	WuXi Apptec	CRO/CMO	69,143	191	**95%**

Source: LSEG Datastream

Sector valuation (P/E)

Exhibit 40: 12m fwd P/E for past 3y (aggregated)
As of Sep 7, 2026



Source: Bloomberg, Goldman Sachs Global Investment Research

Sector valuation (P/S)

Exhibit 41: 12m fwd PS for past 3y (aggregated)
As of Sep 7, 2026



Source: Bloomberg, Goldman Sachs Global Investment Research

China Healthcare comp sheets by sub-sector

Exhibit 42: Comp sheet for selected Biotech and Distributors
Pricing as of Sep 10, 2026

BBG code	Company Name	Mkt cap (US$, mn)	Rating (* CL)	TP	Price (Jun 11)	TP (+/-)	Abs perf			P/E		P/S		Sales growth		EPS growth		ROE	Gross Margin	Net Margin	Net D/ E
							1M	6M	2Y	26E	27E	26E	27E	26E	27E	26E	27E	26E	26E	26E	26E
China Biotech						**Avg**	**(1%)**	**1%**	**140%**	**36.7x**	**244.2x**	**9.0x**	**14.5x**	**49%**	**51%**	**113%**	**49%**	**5%**	**74%**	**5%**	**(35%)**
BGNE US	BeOne	38,021	B	441.30	358.26	23%	3%	20%	87%	44.7x	33.2x	5.8x	5.2x	26%	13%	198%	35%	17%	89%	13%	(83%)
1801 HK	Innovent Biologics	20,953	B	120.60	101.30	19%	7%	20%	135%	48.5x	24.8x	7.6x	5.8x	51%	33%	283%	96%	15%	86%	16%	(75%)
6990 HK	Kelun Biotech	14,141	B	581.20	490.40	19%	(9%)	21%	189%		87.2x	35.0x	18.7x	33%	87%	231%	135%	10%	81%	20%	(68%)
9926 HK	Akeso	11,279	NC	-	96.00	-	(4%)	(16%)	99%	-	90.4x	16.2x	10.6x	53%	52%	-	-	(2%)	81%	(5%)	(52%)
9995 HK	Remegen Co Ltd-H	8,602	NC	-	78.70	-	(9%)	(13%)	532%	9.8x	47.2x	7.8x	13.2x	127%	(41%)	-	-	60%	94%	55%	(5%)
1530 HK	3Sbio	5,192	N	25.74	16.04	60%	(11%)	(27%)	175%	14.7x	11.1x	3.8x	3.5x	(48%)	9%	(73%)	33%	8%	87%	26%	(28%)
LEGN US	Legend Biotech	3,829	B	40.70	21.52	89%	4%	6%	(55%)		67.3x	5.1x	4.1x	-	23%	84%	323%	(4%)	55%	(3%)	(80%)
9969 HK	Innocare Pharma	3,259	B	22.71	14.80	53%	3%	25%	186%	79.0x	145.8x	8.1x	7.1x	10%	15%	-	(46%)	4%	88%	10%	(74%)
300558 CH	Betta Pharma	3,005	S	40.15	48.30	(17%)	(31%)	10%	29%	34.7x	27.5x	5.0x	4.8x	12%	6%	86%	26%	8%	79%	14%	23%
2162 HK	Keymed Biosciences Inc	2,978	B	118.88	78.10	52%	(5%)	44%	112%	17.9x		16.2x	9.7x	64%	66%	-	-	32%	83%	90%	(24%)
ZLAB US	Zai Lab adr	2,724	B	28.68	26.23	9%	12%	38%	32%			6.7x	5.8x	(9%)	16%	(58%)	14%	(47%)	57%	(67%)	(93%)
HCM US	Hutchison China Meditech	2,369	N	14.00	14.09	(1%)	13%	(3%)	(19%)	36.9x	24.5x	3.8x	3.5x	15%	8%	(86%)	51%	5%	45%	10%	(6%)
1952 HK	Everest Medicines	1,401	N	39.66	31.30	27%	15%	(15%)	33%	14.5x	17.6x	2.9x	2.4x	91%	22%	309%	(17%)	12%	77%	20%	(39%)
1672 HK	Ascletis Pharma Inc	1,427	N	13.86	10.29	35%	(8%)	(33%)	961%				232.4x	(100%)		(97%)	(73%)	(39%)		-	(97%)
2616 HK	Cstone Pharmas	1,143	B	9.85	6.07	62%	16%	(17%)	305%		2.5x	17.7x	1.7x	65%	963%	-	-	(50%)	59%	(99%)	(86%)
2171 HK	Carsgen	1,005	S	13.82	13.26	4%	(14%)	(19%)	(11%)			22.9x	9.0x	-	154%	(64%)	90%	(22%)	68%	(59%)	(140%)
1167 HK	Jacobio Pharma	618	N	9.25	6.12	51%	27%	(14%)	266%	10.1x		5.4x	32.7x		(83%)	376%	(157%)	42%	95%	54%	(99%)
1477 HK	Ocumension	548	N	7.92	5.27	50%	(1%)	(23%)	9%			3.4x	3.1x	33%	12%	60%	(6%)	(2%)	51%	(7%)	(5%)
6996 HK	Antengene	299	N	4.84	3.50	38%	(15%)	(18%)	407%	5.6x		2.2x	5.5x	688%	(59%)	239%	(125%)	41%	94%	40%	26%
6622 HK	Zhaoke Ophthalmology Ltd	177	NC	-	2.54	-	0%	(26%)	86%	-	-	-	-	-	-	-	-	-	-	-	(42%)
2126 HK	Jw Therapeutics	107	NC	-	2.01	-	12%	1%	48%	-	-	-	-	-	-	-	-	-	-	-	(43%)
China Distributor						**Avg**	**(1%)**	**(8%)**	**2%**	**10.1x**	**9.6x**	**0.1x**	**0.1x**	**3%**	**5%**	**2%**	**3%**	**7%**	**10%**	**2%**	**43%**
1099 HK	Sinopharm	6,248	N	18.46	15.83	17%	(7%)	(24%)	(6%)	6.1x	5.8x	0.1x	0.1x	(1%)	1%	(3%)	5%	8%	7%	1%	4%
2607 HK	Shanghai Pharma-H	4,172	S	9.97	11.51	(13%)	(3%)	1%	9%	6.4x	7.9x	0.1x	0.1x	4%	2%	(1%)	(19%)	7%	10%	2%	(34%)
600998 CH	Jointown Pharma	3,809	NC	-	5.07	-	2%	(5%)	3%	11.0x	10.0x	0.1x	0.1x	7%	7%	5%	9%	8%	8%	1%	109%
3320 HK	China Resources Pharma	3,578	N	5.64	4.43	27%	(9%)	(2%)	(15%)	6.0x	5.7x	0.1x	0.1x	2%	6%	(1%)	5%	8%	16%	1%	21%

Note: TPs are on a 12-month timeframe; NC = Not Covered; Bloomberg data for NC companies

Source: Goldman Sachs Global Investment Research, Bloomberg

Exhibit 43: Comp sheet for selected MedDevice, Plasma/Vaccine and Diagnostics

Pricing as of Sep 10, 2026

BBg Code	Company Name	Mkt cap (US$, mn)	Rating (* CL)	TP	Price (Jun 11)	TP (+/-)	Abs perf			P/E		P/S		Sales growth		EPS growth		ROE	Gross Margin	Net Margin	Net D/ E
							1M	6M	2Y	26E	27E	26E	27E	26E	27E	26E	27E	26E	26E	26E	26E
China MedDevice						**Avg**	**(3%)**	**(19%)**	**10%**	**25.7x**	**25.2x**	**5.6x**	**4.6x**	**21%**	**18%**	**41%**	**33%**	**11%**	**61%**	**15%**	**(28%)**
300760 CH	Shenzhen Mindray	30,551	B	249.00	169.20	47%	12%	(6%)	(30%)	23.7x	20.7x	5.7x	5.1x	8%	10%	7%	14%	22%	59%	24%	(40%)
688271 CH	United Imaging	12,714	B	182.00	107.24	70%	(5%)	(13%)	4%	38.6x	27.2x	5.1x	4.0x	21%	27%	18%	42%	10%	48%	13%	(12%)
002223 CH	Jiangsu Yuyue	3,816	CS	-	25.55	-	(7%)	(30%)	(19%)	16.8x	14.6x	3.0x	2.7x	8%	11%	3%	15%	11%	51%	18%	0%
300003 CH	Lepu	3,138	N	15.00	11.67	29%	(11%)	(33%)	23%	29.2x	23.1x	3.4x	3.0x	(0%)	11%	(22%)	26%	5%	63%	12%	(1%)
2252 HK	MicroPort MedBot	2,759	B	40.00	21.18	89%	(9%)	(15%)	229%		94.5x	16.2x	10.6x	109%	53%	123%	238%	27%	56%	5%	(40%)
6699 HK	Angelalign	2,121	B	122.00	96.85	26%	5%	36%	73%	65.2x	34.6x	4.3x	3.9x	31%	17%	19%	88%	14%	63%	7%	(64%)
1066 HK	Shandong Weigao	1,847	N	3.86	3.23	20%	(6%)	(35%)	(23%)	9.2x	7.9x	0.9x	0.9x	3%	6%	(16%)	17%	6%	46%	10%	(20%)
300529 CH	Jafron Biomedical	1,845	NC	-	15.51	-	(5%)	(18%)	(36%)	19.0x	17.3x	5.7x	5.2x	8%	8%	18%	10%	17%	80%	30%	(36%)
2675 HK	Edge Medical	1,887	B	60.00	36.66	64%	(7%)	(40%)	(15%)	141.8x	85.0x	14.9x	9.1x	87%	62%	193%	67%	6%	64%	10%	(51%)
300595 CH	Ovctek	1,463	NC	-	10.98	-	(4%)	(29%)	(21%)	15.2x	20.2x	4.7x	4.7x	12%	(0%)	34%	(25%)	11%	69%	28%	(54%)
688277 CH	Tinavi Medical	1,027	N	18.00	15.21	18%	(15%)	(39%)	131%			21.1x	15.7x	17%	35%	20%	18%	(12%)	63%	(45%)	0%
688366 CH	Haohai Biological	947	NC	-	30.19	-	(6%)	(29%)	(49%)	22.7x	21.3x	2.7x	2.6x	(3%)	5%	(32%)	7%	5%	68%	10%	(38%)
1789 HK	AK Medical	649	B	7.00	5.00	40%	(11%)	(17%)	22%	11.3x	9.9x	2.8x	2.5x	11%	12%	22%	15%	14%	64%	25%	(26%)
2235 HK	Microtech	355	N	8.80	6.70	31%	(4%)	(9%)	(16%)	24.5x	13.7x	2.6x	2.0x	43%	26%	147%	78%	7%	58%	11%	(70%)
6609 HK	Heartcare Medical	233	NC	-	48.20	-	(2%)	8%	(10%)	14.6x	10.4x	2.9x	2.1x	34%	35%	29%	41%	9%	72%	21%	(66%)
China Plasma/ vaccine						**Avg**	**(1%)**	**(13%)**	**13%**	**33.6x**	**29.5x**	**6.1x**	**5.3x**	**(0%)**	**13%**	**49%**	**87%**	**4%**	**55%**	**11%**	**(10%)**
300122 CH	Chongqing Zhifei Bio	4,737	B	18.00	13.28	36%	(1%)	(18%)	(38%)		107.3x	4.0x	3.7x	(12%)	10%	92%	126%	(8%)	21%	(15%)	45%
002007 CH	Hualan Biological	3,556	N	13.00	13.05	(0%)	(3%)	(15%)	(13%)	29.1x	26.8x	6.2x	5.9x	(16%)	4%	(13%)	9%	7%	53%	21%	(25%)
300142 CH	Walvax Biotech	3,112	S	7.00	13.06	(46%)	(1%)	10%	29%		141.6x	11.1x	9.1x	(22%)	22%	(77%)	258%	0%	66%	2%	(22%)
300601 CH	Kangtai Biologica	2,105	N	14.00	12.61	11%	(2%)	(10%)	(7%)	152.1x	66.0x	5.4x	4.7x	(3%)	15%	32%	130%	1%	71%	4%	11%
China Diagnostic						**Avg**	**0%**	**(10%)**	**16%**	**28.1x**	**27.5x**	**4.2x**	**3.8x**	**6%**	**11%**	**274%**	**42%**	**8%**	**59%**	**17%**	**(19%)**
300832 CH	SZ New Industries	5,963	B	68.00	50.93	34%	5%	(6%)	(24%)	20.7x	16.9x	7.6x	6.5x	15%	17%	20%	22%	20%	70%	37%	(15%)
603658 CH	Autobio Diagnostics	2,768	NC	-	32.51	-	0%	(7%)	(19%)	16.8x	14.8x	4.1x	3.8x	6%	10%	4%	13%	12%	66%	25%	(34%)
603882 CH	Guangzhou Kingmed	1,837	B	36.00	26.37	37%	(9%)	(8%)	(5%)	30.3x	24.9x	1.9x	1.8x	6%	8%	335%	22%	6%	36%	6%	(30%)
300244 CH	Dian Diagnostics	1,677	N	19.00	18.01	5%	(11%)	(14%)	82%	26.6x	23.5x	1.1x	1.0x	2%	15%	861%	13%	6%	29%	4%	(1%)
300685 CH	Amoy Diagnostics	1,017	B	26.00	17.14	52%	(5%)	(15%)	(9%)	18.6x	15.6x	5.5x	4.7x	4%	15%	1%	19%	17%	84%	29%	(59%)

Note: TPs are on a 12-month timeframe; NC = Not Covered; CS = Coverage Suspended; Bloomberg data for NC and CS companies

Source: Goldman Sachs Global Investment Research, Bloomberg

Exhibit 44: Comp sheet for selected Pharma and Hospital

Pricing as of Sep 10, 2026

BBg Code	Company Name	Mkt cap (US$, mn)	Rating (* CL)	TP	Price (Jun 11)	TP (+/-)	Abs perf			P/E		P/S		Sales growth		EPS growth		ROE	Gross Margin	Net Margin	Net D/ E
							1M	6M	2Y	26E	27E	26E	27E	26E	27E	26E	27E	26E	26E	26E	26E
China Pharma						**Avg**	**(4%)**	**(14%)**	**17%**	**19.7x**	**17.5x**	**3.4x**	**3.0x**	**8%**	**10%**	**41%**	**13%**	**12%**	**62%**	**17%**	**-13%**
600276 CH	Hengrui	44,237	B	73.86	46.26	60%	(15%)	(17%)	4%	33.4x	29.7x	8.7x	7.9x	5%	11%	13%	13%	13%	87%	26%	(71%)
3692 HK	Hansoh Pharma	27,387	B	52.70	36.28	45%	10%	8%	82%	27.4x	26.5x	11.1x	9.7x	13%	14%	22%	3%	19%	92%	41%	(75%)
1093 HK	Cspc Pharma	14,224	B	12.56	9.68	30%	11%	7%	103%	12.0x	13.2x	2.9x	2.9x	25%	1%	103%	(9%)	22%	72%	24%	(23%)
1177 HK	Sino BioPharma	13,088	B	8.65	5.47	58%	7%	(10%)	73%	16.5x	15.9x	2.4x	2.2x	13%	6%	118%	4%	16%	83%	14%	(9%)
000963 CH	Huadong Medicine	7,109	N	35.00	27.20	29%	(6%)	(23%)	(5%)	13.3x	11.5x	1.1x	1.0x	2%	8%	5%	15%	14%	33%	8%	(20%)
2196 HK	Fosun Pharma-H	5,671	N	26.05	17.35	50%	2%	(11%)	43%	11.0x	10.0x	1.0x	0.9x	0%	1%	7%	9%	7%	49%	9%	22%
600079 CH	Humanwell Healthcare	4,586	CS	-	18.86	-	5%	(3%)	(1%)	-	-	-	-	-	-	-	-	-	-	-	22%
867 HK	China Medical System	3,414	B	17.96	10.97	64%	(12%)	(16%)	54%	11.8x	10.5x	2.4x	2.1x	15%	13%	30%	12%	11%	71%	20%	(13%)
000513 CH	Livzon Pharma	3,177	S	23.15	27.16	(15%)	(11%)	(22%)	(21%)	13.2x	14.0x	2.4x	2.3x	(15%)	2%	(9%)	(6%)	13%	61%	18%	(49%)
600867 CH	Tonghua Dongbao	2,339	S	7.00	7.98	(12%)	(5%)	(13%)	5%	27.1x	22.6x	4.8x	4.3x	10%	11%	(53%)	20%	8%	73%	18%	(10%)
9989 HK	Hepalink	751	S	3.63	10.64	(66%)	(0%)	(18%)	24%	11.1x	12.9x	1.1x	1.1x	(9%)	5%	41%	(14%)	4%	32%	10%	0%
China Hospital						**Avg**	**(1%)**	**(13%)**	**15%**	**25.2x**	**22.0x**	**3.0x**	**2.7x**	**8%**	**10%**	**57%**	**17%**	**8%**	**30%**	**9%**	**29%**
300015 CH	Aier Eye Hospital	11,506	B	13.00	8.28	57%	(6%)	(20%)	(11%)	25.0x	17.6x	3.3x	3.1x	5%	7%	(5%)	42%	14%	46%	13%	(14%)
002044 CH	Meinian Onehealth	2,700	NC	-	4.63	-	(4%)	(28%)	34%	42.1x	34.8x	1.7x	1.6x	3%	6%	57%	21%	5%	41%	4%	25%
600763 CH	Topchoice Medical	2,302	S	37.20	35.17	6%	(4%)	(25%)	(15%)	22.0x	22.7x	4.7x	4.5x	7%	6%	25%	(3%)	12%	41%	21%	(17%)
000516 CH	Xian International Medical	1,361	NC	-	4.08	-	(4%)	(23%)	(3%)	-	-	2.2x	2.1x	2%	4%	54%	54%	(5%)	10%	(3%)	130%
6078 HK	Hygeia Healthcare	828	N	12.00	10.36	16%	5%	(18%)	(35%)	10.6x	9.9x	1.3x	1.3x	1%	5%	214%	7%	8%	27%	13%	20%
2273 HK	Gusheng tang	815	B	35.30	26.98	31%	(2%)	1%	(25%)	12.3x	12.3x	1.5x	1.3x	15%	19%	26%	0%	19%	31%	12%	3%
1951 HK	Jinxin Fertility	779	S	2.40	2.20	9%	(0%)	(9%)	(1%)	25.0x	22.1x	1.8x	1.7x	8%	8%	121%	13%	3%	37%	7%	19%

Note: TPs are on a 12-month timeframe; NC = Not Covered; Bloomberg data for NC and CS companies

Source: Goldman Sachs Global Investment Research, Bloomberg

Exhibit 45: Comp sheet for selected CRO/CMO, pharmacy and TCM

Pricing as of Sep 10, 2026

BBg Code	Company Name	Mkt cap (US$, mn)	Rating (* CL)	TP	Price (Jun 11)	TP (+/-)	Abs perf			P/E		P/S		Sales growth		EPS growth		ROE	Gross Margin	Net Margin	Net D/ E
							1M	6M	2Y	26E	27E	26E	27E	26E	27E	26E	27E	26E	26E	26E	26E
China CRO/CMO						Avg	(2%)	29%	182%	119.2x	27.3x	5.9x	4.8x	21%	19%	13%	307%	11%	37%	18%	(8%)
2359 HK	Wuxi Apptec-H	73,145	B	220.10	191.70	15%	(0%)	75%	454%	18.3x	17.6x	7.8x	6.5x	34%	20%	37%	4%	26%	54%	43%	(29%)
2269 HK	Wuxi Biologics	26,517	N	55.80	48.48	15%	6%	34%	338%	32.4x	25.1x	6.8x	5.7x	17%	20%	6%	29%	13%	46%	21%	(14%)
6821 HK	Asymchem Lab	13,200	B	168.20	131.70	28%	11%	58%	85%	39.0x	23.7x	5.4x	4.4x	20%	22%	(3%)	65%	8%	41%	14%	(24%)
2268 HK	Wuxi Xdc Cayman Inc	11,363	B	97.90	72.55	35%	17%	26%	268%	44.3x	28.3x	9.8x	7.4x	37%	33%	18%	57%	20%	36%	22%	(7%)
3759 HK	Pharmaron	6,506	B	37.20	28.20	32%	3%	52%	218%	22.9x	17.5x	2.6x	2.2x	19%	17%	14%	31%	13%	34%	11%	30%
300347 CH	Tigermed	7,019	B	65.90	49.26	34%	(9%)	(13%)	1%	104.4x	41.6x	5.9x	5.1x	17%	16%	(50%)	151%	3%	29%	6%	(3%)
603127 CH	Joinn Laboratories	4,363	NC	-	42.82	-	(16%)	26%	224%	44.8x	56.9x	15.4x	12.6x	14%	22%	139%	(21%)	7%	24%	38%	(31%)
300363 CH	Porton Pharma Solutions	1,611	NC	-	19.90	-	(3%)	(6%)	69%	1170.6x	30.0x	2.8x	2.4x	14%	15%	(91%)	3,800%	0%	32%	0%	8%
1521 HK	Frontage Holdings	307	S	1.07	1.20	(11%)	(8%)	7%	118%	25.6x	20.3x	1.0x	0.9x	16%	10%	76%	26%	7%	27%	4%	2%
China Pharmacy						Avg	3%	(8%)	4%	13.9x	12.4x	0.6x	0.5x	6%	7%	34%	12%	12%	29%	4%	(10%)
603939 CH	Yifeng Pharmacy Chain	4,122	B	32.00	22.82	40%	3%	(5%)	20%	14.9x	13.7x	1.1x	1.0x	5%	6%	10%	9%	15%	39%	7%	(10%)
603233 CH	Dashenlin Pharma G	3,124	B	26.00	18.41	41%	5%	(5%)	37%	14.5x	12.6x	0.7x	0.6x	10%	12%	16%	15%	19%	35%	5%	(46%)
600511 CH	China National Medicines	3,022	NC	-	26.88	-	(2%)	(12%)	(7%)	9.8x	9.3x	0.4x	0.3x	5%	5%	3%	6%	10%	6%	4%	(37%)
603883 CH	Laobaixing Pharmacy Chain	1,549	N	17.00	13.70	24%	11%	(4%)	(24%)	15.6x	14.9x	0.4x	0.4x	8%	8%	72%	5%	10%	32%	3%	12%
002727 CH	Yixintang Pharma G	981	NC	-	11.24	-	(1%)	(15%)	(8%)	14.7x	11.8x	0.4x	0.4x	3%	5%	67%	25%	6%	33%	3%	32%
China TCM						Avg	(6%)	(15%)	(10%)	21.9x	16.4x	2.8x	2.7x	(0%)	7%	42%	34%	11%	57%	15%	(18%)
000538 CH	Yunnan Baiyao	13,443	NC	-	50.57	-	(0%)	(11%)	(5%)	16.2x	15.0x	2.1x	2.0x	3%	4%	8%	8%	14%	29%	13%	(28%)
600436 CH	Pientzehuang	10,962	B	176.00	122.68	43%	(10%)	(22%)	(39%)	36.3x	34.7x	9.1x	8.9x	(10%)	2%	(6%)	5%	13%	39%	25%	(14%)
000999 CH	China Resources Sanjiu Med	6,117	NC	-	24.67	-	(2%)	(17%)	(29%)	11.5x	10.6x	1.2x	1.2x	5%	7%	4%	9%	15%	54%	11%	(2%)
600085 CH	Beijing Tongrentang	4,939	NC	-	24.17	-	(3%)	(20%)	(29%)	23.9x	21.4x	1.9x	1.7x	4%	8%	17%	12%	9%	44%	7%	(32%)
000423 CH	Dong-E-E-Jiaoco	4,505	NC	-	47.26	-	(11%)	(10%)	(7%)	15.6x	13.8x	4.1x	3.7x	9%	11%	12%	13%	18%	73%	27%	(88%)
002603 CH	SJZ Yiling Pharma	3,923	NC	-	15.76	-	(7%)	(7%)	4%	17.6x	15.2x	3.1x	2.9x	8%	9%	16%	16%	13%	65%	18%	(17%)
600566 CH	Hubei Jumpcan Pharma	3,534	NC	-	25.74	-	(1%)	(5%)	(7%)	12.8x	11.9x	3.8x	3.5x	1%	6%	4%	8%	12%	79%	29%	(74%)
600535 CH	Tasly Pharma	3,254	NC	-	14.62	-	(7%)	2%	2%	16.6x	14.2x	2.5x	2.3x	6%	9%	19%	17%	10%	68%	15%	(11%)
600129 CH	Chongqing Taiji Indus Grp	1,144	NC	-	13.93	-	(14%)	(17%)	(38%)	14.1x	11.8x	-	-	-	-	350%	19%	-	-	-	149%
570 HK	China TCM	857	NC	-	1.34	-	(8%)	(32%)	(69%)	-	12.7x	0.4x	0.4x	(12%)	4%	(33%)	200%	1%	-	(4%)	(6%)

Note: TPs are on a 12-month timeframe; NC = Not Covered; Bloomberg data for NC companies

Source: Goldman Sachs Global Investment Research, Bloomberg

Methodologies

Below, we provide an overview of the methodologies used throughout this report:

- **Universe 1:** The analysis is based on ~200 China Healthcare related stocks, excluding small cap stocks with no consensus estimates, e.g. for valuation/estimates related.
- **Universe 2:** ~500 China Healthcare related stocks, including small caps, e.g. for sector dispersion, trading flows.
- **Valuation (P/E, P/S):** Based on universe 1, calculated by aggregated market cap divided by aggregated 12m forward consensus estimates.
- **Trading flow:** Based on universe 2, calculated based on aggregated sum of the monthly average trading value.
- **Sector dispersion:** Based on universe 2; the difference between the average performance of the top 20% and bottom 20% within the sector.
- For sector specific analysis involving both onshore/offshore, we select H shares for dual listed A/H and US ADR for dual listed H/ADR.

Glossary

AMD: Age-related macular degeneration

BD: Business development

CRO/CDMO: Contract Research Organization/Contract Development and Manufacturing Organization

NHSA: National Healthcare Security Administration

MIS: Minimally invasive surgery

NRDL: National reimbursement distribution list

NHI: National Healthcare Insurance

TMVR: Transcatheter Mitral Valve Repair

TTVR: Transcatheter Tricuspid Valve Replacement

ADC: Antibody-drug conjugate

TCM: Traditional Chinese Medicine

VBP: Volume-based Procurement

DRG/DIP: Diagnosis Related Groups/Big Data Diagnosis-Intervention Packet